Business Description
RemeGen Co Ltd
ISIN : CNE1000048G6
Share Class Description:
FRA:REG: Class HCompare
Compare
Traded in other countries / regions
09995.Hong Kong688331.ChinaREG.GermanyREGMF.USA IPO Date
2021-03-15Description
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.37 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.9 | |||||
| Debt-to-EBITDA | -1.88 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 3.07 | |||||
| Beneish M-Score | -2.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -13.8 | |||||
| 3-Year EPS without NRI Growth Rate | -14.6 | |||||
| 3-Year FCF Growth Rate | -12.9 | |||||
| 3-Year Book Growth Rate | -7.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 33.18 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 43.08 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.39 | |||||
| 9-Day RSI | 34.96 | |||||
| 14-Day RSI | 41.33 | |||||
| 3-1 Month Momentum % | 46.58 | |||||
| 6-1 Month Momentum % | -31.85 | |||||
| 12-1 Month Momentum % | -49.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.51 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.53 | |||||
| Days Inventory | 836.09 | |||||
| Days Sales Outstanding | 66.21 | |||||
| Days Payable | 204.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.6 | |||||
| Shareholder Yield % | -8.95 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.11 | |||||
| Operating Margin % | -110.32 | |||||
| Net Margin % | -113.79 | |||||
| FCF Margin % | -155.18 | |||||
| ROE % | -45.66 | |||||
| ROA % | -27.77 | |||||
| ROIC % | -38.18 | |||||
| 3-Year ROIIC % | -30 | |||||
| ROC (Joel Greenblatt) % | -42.3 | |||||
| ROCE % | -34.22 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.67 | |||||
| PB Ratio | 3.02 | |||||
| Price-to-Tangible-Book | 3.05 | |||||
| EV-to-EBIT | -10.66 | |||||
| EV-to-Forward-EBIT | -17.17 | |||||
| EV-to-EBITDA | -12.95 | |||||
| EV-to-Forward-EBITDA | -24.42 | |||||
| EV-to-Revenue | 11.76 | |||||
| EV-to-Forward-Revenue | 6.3 | |||||
| EV-to-FCF | -7.57 | |||||
| Earnings Yield (Greenblatt) % | -9.38 | |||||
| FCF Yield % | -14.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
RemeGen Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 179.101 | ||
| EPS (TTM) (€) | -0.379 | ||
| Beta | 0.39 | ||
| 3-Year Sharpe Ratio | -0.25 | ||
| 3-Year Sortino Ratio | -0.34 | ||
| Volatility % | 100.31 | ||
| 14-Day RSI | 41.33 | ||
| 14-Day ATR (€) | 0.079312 | ||
| 20-Day SMA (€) | 2.07 | ||
| 12-1 Month Momentum % | -49.05 | ||
| 52-Week Range (€) | 1.21 - 4.38 | ||
| Shares Outstanding (Mil) | 544.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RemeGen Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RemeGen Co Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
RemeGen Co Ltd Frequently Asked Questions
What is RemeGen Co Ltd(FRA:REG)'s stock price today?
The current price of FRA:REG is €1.86. The 52 week high of FRA:REG is €4.38 and 52 week low is €1.21.
When is next earnings date of RemeGen Co Ltd(FRA:REG)?
The next earnings date of RemeGen Co Ltd(FRA:REG) is .
Does RemeGen Co Ltd(FRA:REG) pay dividends? If so, how much?
RemeGen Co Ltd(FRA:REG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers